Migraine Study in Adolescent Patients

Model scores of the 29,894 trials active now.

Model score 10% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (734 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 3.8% (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 53.3% (lowers risk) · Drug's FDA history
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subject hassubject isischemicevidenceheart
  Phrases that lowered it: screeningand safetyefficacy andsafety ofpain
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor's past trials: 873 (raises risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 502 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 5.4% (lowers risk) · Drug's FDA history
• Number of arms: 4 (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 12 (lowers risk) · Who can join
• Disease area, neurology: Yes (raises risk) · Disease area
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Keywords listed: 9 (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Treximet Early Intervention Adolescent Migraine NCT01016678 · started 2010 · scored riskier than 22% of active trials completed
• A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses. NCT00989625 · started 2008 · scored riskier than 5% of active trials completed
• Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents NCT00963937 · started 2009 · scored riskier than 11% of active trials completed
• The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine NCT00724815 · started 2009 · scored riskier than 9% of active trials completed
• TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults NCT00573170 · started 2008 · scored riskier than 13% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.